MedTrace Logo

AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation

NCT06281496 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-01

No results posted yet for this study

Summary

A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.

Conditions

  • Hematological Diseases

Interventions

BEHAVIORAL

AlloCare

Survivorship supportive care

Sponsors & Collaborators

  • Danish Cancer Society

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Mette Schaufuss Engedal, MSc · Rigshospitalet. Department of Hematology. Denmark

  • Mary Jarden · Rigshospitalet. Department of Hematology. Denmark

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2027-10-01
Completion
2027-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06281496 on ClinicalTrials.gov